AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16835600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15915396 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) epinephrine
Number of subjects: 63
Study 15915396 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) epinephrine
Number of subjects: 63
Study 15915396 — intervention group
Group type: COMPARATOR
Intervention: Control (H1 and H2 receptor blockade)
Number of subjects: 63
Study 12503018 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible bioabsorbable cement restrictor with decompression valves
Number of subjects: 108
Study 12503018 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia without oxygen enrichment
Number of subjects: 108
Study 12503018 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with optional oxygen delivery
Number of subjects: 108
Study 11382873 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcolepsy-cataplexy
Number of subjects: 0
Study 11382873 — intervention group
Group type: COMPARATOR
Intervention: Habitual nappers
Number of subjects: 0
Study 7899535 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5-HTP, 200 mg PO)
Number of subjects: 47
Study 7899535 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1 mg PO)
Number of subjects: 47
Study 2672773 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate diet (39% fat, P:S ratio 0.30 or 1.00)
Number of subjects: 31
Study 2672773 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate diet (19% fat, same P:S ratio)
Number of subjects: 31
Study 857761 — intervention group
Group type: EXPERIMENTAL
Intervention: High epidural analgesia (bupivacaine injections into the epidural space)
Number of subjects: 30
Study 857761 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl analgesia during surgery and nicomorphine afterwards
Number of subjects: 30
Study 30859858 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor cycling (20-min time trial)
Number of subjects: 20
Study 30859858 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor cycling (20-min time trial)
Number of subjects: 20
Study 30859858 — intervention group
Group type: COMPARATOR
Intervention: Comparison of indoor vs outdoor cycling
Number of subjects: 20
Study 28551167 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab (6 mg/50 μl)
Number of subjects: 89
Study 28551167 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept (2 mg/50 μl)
Number of subjects: 89
Study 28551167 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 89
Study 28551167 — intervention group
Group type: COMPARATOR
Intervention: Brolucizumab and Aflibercept
Number of subjects: 89
Study 26418164 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight acceptance
Number of subjects: 394
Study 23192700 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy concurrently with weekly cisplatin (30 mg/m²), followed by adjuvant chemotherapy (cisplatin 80 mg/m² on Day 1 and fluorouracil 800 mg/m² on Days 1-5 for 3 cycles)
Number of subjects: 121
Study 23192700 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy concurrently with weekly cisplatin
Number of subjects: 121
Study 23192700 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 121
Study 21656149 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-Training
Number of subjects: 24
Study 21656149 — intervention group
Group type: COMPARATOR
Intervention: BP-Monitoring
Number of subjects: 24
Study 19328263 — intervention group
Group type: EXPERIMENTAL
Intervention: It's All About Kids nutrition component (six weekly 30-minute experiential lessons)
Number of subjects: 140
Study 16772358 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 66
Study 16772358 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 66
Study 15562177 — intervention group
Group type: EXPERIMENTAL
Intervention: Golf specific warm up programme (performed immediately prior to play and after performing it five times a week for 5 weeks)
Number of subjects: 20
Study 15562177 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warm up programme)
Number of subjects: 20
Study 15562177 — intervention group
Group type: EXPERIMENTAL
Intervention: Golf specific warm up programme
Number of subjects: 20
Study 11591407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.125 g of Crinone 4% and 8% or 2.25 g of Crinone 8% (containing 45, 90, and 180 mg of P per application)
Number of subjects: 0
Study 11591407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal P gel Crinone administered to estrogenized women
Number of subjects: 0
Study 11591407 — intervention group
Group type: EXPERIMENTAL
Intervention: Analyzing uterine contraction frequency on accelerated image sequences
Number of subjects: 0
Study 9022867 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression adjustment for covariates
Number of subjects: 0
Study 7524044 — intervention group
Group type: EXPERIMENTAL
Intervention: Entex LA tablets (sustained-release, carbomer-based)
Number of subjects: 15
Study 7524044 — intervention group
Group type: EXPERIMENTAL
Intervention: Entex PSE tablets (sustained-release, hydroxypropylcellulose-based)
Number of subjects: 15
Study 7524044 — intervention group
Group type: COMPARATOR
Intervention: Branded competitor products (sustained-release)
Number of subjects: 15
Study 3052051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3052051 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 13
Study 3052051 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 13
Study 4879059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole
Number of subjects: 103
Study 4879059 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 31254047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyaluronic acid/chondroitin sulfate (HA/CS)
Number of subjects: 68
Study 31254047 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 68
Study 31254047 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HA/CS and CS
Number of subjects: 68
Study 28387939 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888)
Number of subjects: 71
Study 28387939 — intervention group
Group type: EXPERIMENTAL
Intervention: M8 metabolite
Number of subjects: 71
Study 28387939 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 71
Study 24965306 — intervention group
Group type: EXPERIMENTAL
Intervention: Home enteral nutrition (HEN)
Number of subjects: 456
Study 22679745 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-positive neuroprotectors citicoline and choline alfoscerate
Number of subjects: 52
Study 22679745 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotective therapy
Number of subjects: 52
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Proven etiology (identified neurologic disease)
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: No identified etiology (no neurologic disease)
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Not fully investigated (major information missing)
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiologies classified as prenatal
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiologies classified as perinatal
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiologies classified as postnatal
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Other etiologies
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic‐ischemic encephalopathy (HIE)
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal abnormalities
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Malformations
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberous sclerosis complex (TSC)
Number of subjects: 207
Study 20726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular leukomalacia or hemorrhage
Number of subjects: 207
Study 19089263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing Aloe vera
Number of subjects: 30
Study 19089263 — intervention group
Group type: COMPARATOR
Intervention: Fluoridated dentifrice
Number of subjects: 30
Study 15953322 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate division of tongue-tie
Number of subjects: 57
Study 15953322 — intervention group
Group type: COMPARATOR
Intervention: Intensive lactation consultant support (control)
Number of subjects: 57
Study 11861668 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Change (TLC)/Step 2 diet
Number of subjects: 36
Study 11861668 — intervention group
Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 36
Study 10417035 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical care program (group A)
Number of subjects: 83
Study 10417035 — intervention group
Group type: COMPARATOR
Intervention: Standard care (group B)
Number of subjects: 83
Study 7593525 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin‐releasing hormone analogues (GnRHa)
Number of subjects: 140
Study 2281392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nucleinate (SN)
Number of subjects: 30
Study 2281392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7243514 — intervention group
Group type: EXPERIMENTAL
Intervention: Double wall in a forced convection‐heated incubator
Number of subjects: 10
Study 31676252 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for diabetic kidney disease (DKD) risk
Number of subjects: 436
Study 31065958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual method (DM) of indocyanine green fluorescence (ICG‐F) plus a radioisotope (RI), n = 58
Number of subjects: 130
Study 31065958 — intervention group
Group type: COMPARATOR
Intervention: Radioisotope (RI) only, n = 64
Number of subjects: 130
Study 31065958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual method (DM) of indocyanine green fluorescence (ICG‐F) plus a radioisotope (RI)
Number of subjects: 130
Study 31065958 — intervention group
Group type: COMPARATOR
Intervention: Radioisotope (RI) only
Number of subjects: 130
Study 31065958 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence (ICG‐F)
Number of subjects: 130
Study 31065958 — intervention group
Group type: COMPARATOR
Intervention: Radioisotope (RI)
Number of subjects: 130
Study 28706429 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose sodium phosphate (NaP) tablets with 2 L of clear liquid (30 tablets)
Number of subjects: 200
Study 28706429 — intervention group
Group type: COMPARATOR
Intervention: 2 L of polyethylene glycol (PEG)
Number of subjects: 200
Study 26088013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 557
Study 24238686 — intervention group
Group type: EXPERIMENTAL
Intervention: BITSEA
Number of subjects: 2106
Study 24238686 — intervention group
Group type: COMPARATOR
Intervention: ASQ:SE
Number of subjects: 2106
Study 24238686 — intervention group
Group type: COMPARATOR
Intervention: KIPPPI
Number of subjects: 2106
Study 21331516 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle to pulmonary artery shunt, n = 25
Number of subjects: 44
Study 21331516 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt, n = 19
Number of subjects: 44
Study 21331516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 19352498 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfadoxine‐pyrimethamine (SP)
Number of subjects: 272
Study 19352498 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorproguanil‐dapsone (CD)
Number of subjects: 272
Study 19352498 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfadoxine‐pyrimethamine + amodiaquine (SP+AQ)
Number of subjects: 272
Study 19352498 — intervention group
Group type: EXPERIMENTAL
Intervention: amodiaquine + artesunate (AQ+AS)
Number of subjects: 272
Study 17532786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine therapy (group I)
Number of subjects: 221
Study 17532786 — intervention group
Group type: COMPARATOR
Intervention: Persistently detectable serum HBV-DNA (group II)
Number of subjects: 221
Study 17047260 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based calculation algorithm with a dose kernel scaled for heterogeneities
Number of subjects: 16
Study 17047260 — intervention group
Group type: COMPARATOR
Intervention: No model-based calculation algorithm or model-based calculation algorithm with a dose kernel unscaled for heterogeneities
Number of subjects: 16
Study 12660409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr (4 x 5 g x day(‐1) x 5 days)
Number of subjects: 18
Study 12660409 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose+Cr (1 g x (‐1) of body mass twice per day)
Number of subjects: 18
Study 12660409 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise+Cr (60 min of daily muscular (repeated‐sprint) exercise)
Number of subjects: 18
Study 12660409 — intervention group
Group type: COMPARATOR
Intervention: 0 g x day(‐1) maintenance
Number of subjects: 18
Study 12660409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g x day(‐1) maintenance
Number of subjects: 18
Study 12660409 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g x day(‐1) maintenance
Number of subjects: 18
Study 10100060 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial BP (i.a.)
Number of subjects: 93
Study 10100060 — intervention group
Group type: COMPARATOR
Intervention: Sphygmomanometric BP (sphygmo)
Number of subjects: 93
Study 10100060 — intervention group
Group type: COMPARATOR
Intervention: 24-h ambulatory blood pressure (ABPM)
Number of subjects: 93
Study 10100060 — intervention group
Group type: COMPARATOR
Intervention: Oscillometric BP (Dinamap)
Number of subjects: 93
Study 8693954 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 8693954 — intervention group
Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 0
Study 1649539 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 1649539 — intervention group
Group type: COMPARATOR
Intervention: Thiopental/Isuflurane
Number of subjects: 20
Study 6619453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1N HCl infusion at 4 to 5 A.M.
Number of subjects: 9
Study 6619453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1N HCl infusion at midnight
Number of subjects: 9
Study 6619453 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion at midnight
Number of subjects: 9
Study 6619453 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion at 4 to 5 A.M.
Number of subjects: 9
Study 6619453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1N HCl infusion at 4 to 5 A.M. in patients with a negative Bernstein test
Number of subjects: 9
Study 31852816 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 2443
Study 31852816 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 2443
Study 31852816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2443
Study 31852816 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (both dosages)
Number of subjects: 2443
Study 31091374 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib (300 mg per day) plus Fulvestrant (500 mg every 28 days and once on day 15)
Number of subjects: 572
Study 31091374 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Fulvestrant
Number of subjects: 572
Study 31091374 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib-fulvestrant
Number of subjects: 572
Study 31091374 — intervention group
Group type: COMPARATOR
Intervention: Placebo-fulvestrant
Number of subjects: 572
Study 28437508 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 91
Study 28437508 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 91
Study 28437508 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 91
Study 25737487 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-blood pressure monitoring (home blood pressure monitor and training)
Number of subjects: 900
Study 25737487 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 900
Study 23438190 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Shoes (MS)
Number of subjects: 14
Study 23438190 — intervention group
Group type: COMPARATOR
Intervention: Traditional Shoes (TS)
Number of subjects: 14
Study 21784413 — intervention group
Group type: EXPERIMENTAL
Intervention: COMET + treatment-as-usual (TAU)
Number of subjects: 93
Study 21784413 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 93
Study 19161608 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive self-help programme (StopSite)
Number of subjects: 0
Study 19161608 — intervention group
Group type: COMPARATOR
Intervention: Online self-help guide
Number of subjects: 0
Study 16763973 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade IV gliomas
Number of subjects: 67
Study 16763973 — intervention group
Group type: COMPARATOR
Intervention: Grade II and III gliomas
Number of subjects: 67
Study 15313689 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually staged nutrition group (individualized group), 50 patients
Number of subjects: 100
Study 15313689 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition group (TPN group), 50 patients
Number of subjects: 100
Study 11273211 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.5 mg/kg daily for 8 weeks
Number of subjects: 41
Study 11273211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9294477 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM + MPA (medroxyprogesterone acetate 500 mg/day orally)
Number of subjects: 215
Study 9294477 — intervention group
Group type: COMPARATOR
Intervention: MPA (substituted for tamoxifen)
Number of subjects: 215
Study 9294477 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM + MPA
Number of subjects: 215
Study 9294477 — intervention group
Group type: COMPARATOR
Intervention: MPA
Number of subjects: 215
Study 8361795 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-in-oil emollient cream applied twice a day
Number of subjects: 34
Study 8361795 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control) group
Number of subjects: 34
Study 3779498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-sequence induction with thiopentone (5 mg X kg‐1) and succinylcholine
Number of subjects: 14
Study 3779498 — intervention group
Group type: COMPARATOR
Intervention: Elective induction with thiopentone (5 mg X kg‐1) and succinylcholine
Number of subjects: 14
Study 3779498 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rapid-sequence and elective induction
Number of subjects: 14
Study 31713350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 1 mg
Number of subjects: 25
Study 31713350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg
Number of subjects: 25
Study 31713350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 30 mg
Number of subjects: 25
Study 31713350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg (single dose) followed by 15 mg twice daily for 5 days
Number of subjects: 25
Study 31713350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31713350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (all doses)
Number of subjects: 25
Study 30095153 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet+Vest (weighted vest use during a 22-week behavioral diet intervention targeting 10% weight loss, 1100-1300 kcals/day)
Number of subjects: 37
Study 30095153 — intervention group
Group type: COMPARATOR
Intervention: Diet (22-week behavioral diet intervention targeting 10% weight loss, 1100-1300 kcals/day)
Number of subjects: 37
Study 28253904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile telephone-delivered intervention including printed materials, one-on-one discussion, and 6 weeks of personalized text messages.
Number of subjects: 100
Study 28253904 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 100
Study 26276658 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 425
Study 26276658 — intervention group
Group type: COMPARATOR
Intervention: No-statin treatment (Control)
Number of subjects: 425
Study 24228540 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (homologue Chinese drugs preparations)
Number of subjects: 1200
Study 24228540 — intervention group
Group type: COMPARATOR
Intervention: Control group (model Chinese drugs)
Number of subjects: 1200
Study 21348544 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol-containing gel applied daily for 60 days on the right side of the face
Number of subjects: 20
Study 21348544 — intervention group
Group type: COMPARATOR
Intervention: Vehicle hydrogel applied on the left side of the face as control
Number of subjects: 20
Study 21348544 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol-containing gel
Number of subjects: 20
Study 21348544 — intervention group
Group type: COMPARATOR
Intervention: Vehicle hydrogel
Number of subjects: 20
Study 18301313 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol-400 (400 mgI/mL, 726 mOsm/kg, N = 76)
Number of subjects: 148
Study 18301313 — intervention group
Group type: COMPARATOR
Intervention: iodixanol-320 (320 mgI/mL, 290 mOsm/kg, N = 72)
Number of subjects: 148
Study 18301313 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of mean SCr change
Number of subjects: 148
Study 17159170 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial implants
Number of subjects: 51
Study 17159170 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed tibial implants
Number of subjects: 51